Ph 1a/1b trial of OMX-040 in patients with advanced solid tumors advanced to expansion phase in kidney cancer and angiosarcoma
Apollon Papadimitriou, Ph.D., Chief Executive Officer of iOmx, concluded: “Kicking-off the Phase Ib segment of the OMX-0407 trial is a key development milestone for iOmx. The dose escalation data, including one long-lasting complete response in an indication of high medical need and additional signs of anti-tumor activity in other patients is very strong. We are confident that we are progressing towards providing a clinically meaningful, differentiated therapy for patients failing current cancer treatments and expect to report topline clinical proof-of-concept data by early 2026.”
Share:
More News
“Our goal is not simply to complete a Phase 1 trial; it is to deliver a re-sensitization solution that changes the post-progression treatment paradigm and positions Kairos as the essential complement to the EGFR-targeted therapy market with this clean safety profile now confirmed across 13 patients,” said Dr. John Yu,
Dr. Michael GE, CEO of Kelun-Biotech, stated: “We are delighted to see that sac-TMT combined with pembrolizumab has achieved exciting positive results compared with immunotherapy plus chemotherapy in the first-line treatment of patients with PD-L1-negative NSCLC. This ADC plus immunotherapy regimen has previously demonstrated superior efficacy over immunotherapy monotherapy in
“This Fast Track designation represents another important regulatory milestone for Oncolytics and reflects the significant progress we have made over the past twelve months in advancing pelareorep toward potential registration,” said Jared Kelly, Chief Executive Officer of Oncolytics. “During that time, we have received Fast Track designation in both metastatic
“These findings build upon the well-established role of KEYTRUDA in endometrial cancer, one of the few cancers with rising incidence rates,” said Dr. Gursel Aktan, vice president, global clinical development, Merck Research Laboratories. “We are committed to helping women facing this disease by advancing potential treatment options. We thank the